Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]
The prognosis of patients with early lung cancer is better, but many patients with lung cancer are diagnosed with advanced stage, and the overall five-year survival rate is only about […]